Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

Company Overview

Cardiol Therapeutics Inc. is a Canadian clinical-stage biotechnology company focused on developing therapies for inflammatory diseases of the heart and other cardiovascular conditions. The company is headquartered in Burlington, Ontario, and its shares trade on the Nasdaq Capital Market under the symbol CRDL.

Cardiol’s lead product candidate, CardiolRx, is a pharmaceutical formulation of cannabidiol being investigated for its potential anti-inflammatory and cardioprotective properties. The company’s research has focused on conditions including acute myocarditis, an inflammation of the heart muscle, and recurrent pericarditis, an inflammatory disorder affecting the sac surrounding the heart.

Cardiol conducts clinical development activities through research and trial programs in North America and other regions. The company is led by David Elsley, who serves as president and chief executive officer, with scientific and medical programs supported by researchers and clinicians specializing in cardiovascular disease and inflammation.

Key Stats

• Today's Range: $1.18 to $1.24
• 50-Day Range: $1.18 to $2.29
• 52-Week Range: $0.88 to $2.34
• Volume: 2.03 million shs
• Average Volume: 1.65 million shs
• Market Capitalization: $142.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Cardiol Therapeutics Stock Analysis - MarketRank™

Cardiol Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 246th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cardiol Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cardiol Therapeutics has a consensus price target of $10.00, representing about 733.3% upside from its current price of $1.20.

Amount of Analyst Coverage

Cardiol Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cardiol Therapeutics are expected to decrease in the coming year, from ($0.19) to ($0.24) per share.

Price to Book Value per Share Ratio

Cardiol Therapeutics has a P/B Ratio of 10.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.73% of the float of Cardiol Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cardiol Therapeutics has a short interest ratio ("days to cover") of 3.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardiol Therapeutics has recently decreased by 7.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiol Therapeutics does not currently pay a dividend.

Dividend Growth

Cardiol Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Cardiol Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cardiol Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for CRDL on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

4 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.25% of the stock of Cardiol Therapeutics is held by insiders.

Percentage Held by Institutions

12.49% of the stock of Cardiol Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRDL
• CIK: 1702123
• Web: www.cardiolrx.com
• Phone: (289) 910-0850
• Fax: N/A
• Employees: 18
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Cardiol Therapeutics: $10.00
• High Price Target: $11.00
• Low Price Target: $9.00
• Potential Upside/Downside: +733.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -180.44%
• Return on Assets: -140.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.55
• Quick Ratio: 5.55

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 10.91

Miscellaneous

• Outstanding Shares: 118,930,000
• Free Float: 112,686,000
• Market Cap: $142.72 million
• Optionable: Not Optionable
• Beta: 0.88